Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Abbott Laboratories

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Savara (SVRA), AptarGroup (ATR) and Abbott Laborator...

Analysts Offer Insights on Healthcare Companies: Savara (SVRA), AptarGroup (ATR) and Abbott Laboratories (ABT)

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories, with a price target of $112.00. Th...

Wells Fargo Keeps Their Buy Rating on Abbott Laboratories (ABT)

Abbott Laboratories ( ($ABT) ) just unveiled an update. On August 20, 2026, Abbott announced agreements with three law firms to settle the Gill cas...

Abbott settles major preterm formula litigation claims

Insiders have been trading these 5 stocks: (($ENPH)), (($OPEN)), (($ABT)), (($TTWO)) and (($NDAQ)). Here is a breakdown of their recent trades and ...

Enphase, Opendoor, Abbott, Take-Two, Nasdaq Insider Shocks

A federal judge in Illinois has dismissed the amended complaint in an investor lawsuit against Abbott Laboratories (ABT) over statements tied to th...

Court Dismisses Amended Securities Complaint Against Abbott Laboratories 

In a report released today, Joanne Wuensch from Citi maintained a Buy rating on Abbott Laboratories, with a price target of $125.00. According to T...

Abbott Laboratories (ABT) Receives a Buy from Citi

Abbott Laboratories ($ABT) announced an update on their ongoing clinical study. The PULSE Study is a new trial looking at early treatment for atria...

Early AF Treatment on Trial: What Abbott’s PULSE Study Could Mean for Investors

Abitare In SpA ( ($IT:ABT) ) has shared an update. Abitare In S.p.A. has made available the minutes of its shareholders’ meeting held on July 20, 2...

Abitare In Publishes Minutes of July 20 Shareholders’ Meeting

Abits Group ( ($ABTS) ) just unveiled an update. On August 6, 2026, Abits Group CEO Conglin Deng transferred all of his beneficial interests in the...

Abits Group Hands 47% Voting Control to ARC, Reshapes Board and Governance in August 2026

In a report released today, Travis Steed from Bank of America Securities maintained a Buy rating on Abbott Laboratories, with a price target of $11...

Abbott Laboratories (ABT) Receives a Buy from Bank of America Securities

Abitare In SpA ( ($IT:ABT) ) has shared an update. Abitare In S.p.A. reported consolidated revenues of €55.3 million and EBITDA of €5.5 million for...

Abitare In Hit by Milan Permit Slowdown as It Reshapes Model with Techbau Deal

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Abbott Laboratories (ABT), Lemaitre Vascular (LMAT) and Harmony B...

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Lemaitre Vascular (LMAT) and Harmony Biosciences Holdings (HRMY)

Abitare In SpA ( ($IT:ABT) ) has provided an update. Abitare In S.p.A. has secured approval from Borsa Italiana for the voluntary removal of its or...

Abitare In to Exit Borsa Italiana’s STAR Segment but Remain on Euronext Milan

American Bitcoin Corp ( ($ABTC) ) has provided an update. On July 31, 2026, American Bitcoin Corp.’s board appointed Paul Sacks as Interim Chief Fi...

American Bitcoin Names Paul Sacks Interim Chief Financial Officer

The S&P 500 Index (SPX) has gained 9.4% so far this year, but a few low‑cost ETFs are doing even better. These funds do not rely on big tech stocks


Here’s Why These 3 ETFs Are Beating the S&P 500 Index in 2026

An update from Abitare In SpA ( ($IT:ABT) ) is now available. Abitare In has completed the sale to Techbau New Living of equity interests in 14 spe...

Abitare In closes €141 million project sale and seeks exit from STAR segment

Investors searching for regular cash payments can look to Abbott Laboratories ($ABT), CH Robinson ($CHRW), and Linde ($LIN). Top analysts covering ...

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Power Your Cash Flow, 7/30/26

Dividend ETFs are one of the most popular ways to earn passive income, but choosing the right fund isn’t always easy. Among the leading options are...

SCHD vs. VYMI: Which Dividend ETF Comes Out on Top?

Kalray SA ( ($FR:ALKAL) ) has provided an update. Bull and Kalray have formed a strategic partnership to co-develop next-generation network interco...

Kalray and Bull forge strategic alliance on Ultra Ethernet AI networks

Abitare In SpA ( ($IT:ABT) ) has shared an announcement. Abitare In S.p.A. has published its sixth Sustainability Report for the 2025 financial yea...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABT	$115.47	-1.03%	1.04M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABT	$115.47	-1.0%	1.04M
3
4
5
6

ABT

Get Abbott Laboratories Data in Excel

Get Abbott Laboratories Data in Excel